Curing hepatocellular carcinomatosis with biologic therapy and surgery: Achieving the impossible?

Journal of Surgical Oncology

Volumn 97, Issue 1, 2008, Pages 82-84

  Thomas, Melanie B ^a,b   Tetzlaff, Eric ^a   Lozano, Richard ^a   Samp, Leigh ^a   Butler, Charles E ^a   Gannon, Christopher ^a   Hamilton, Stanley ^a   Vauthey, Jean Nicholas ^a   Abdalla, Eddie ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE   (United States)

Author keywords

Hepatocellular carcinoma; Resection; Targeted chemotherapy

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BEVACIZUMAB; ERLOTINIB; FLUOROURACIL;

ADULT; ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CARCINOMATOUS PERITONITIS; CASE REPORT; CLINICAL TRIAL; CONFERENCE PAPER; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; LIVER CARCINOMA; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; SALVAGE THERAPY; SYSTEMIC THERAPY; TREATMENT RESPONSE;

EID: 38149053003     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20898     Document Type: Conference Paper

References (34)

1. Shiratori M, Nagashima I, Takada T, et al.: Successful treatment of ruptured hepatocellular carcinoma with intraperitoneal injection of OK-432. J Hepatobiliary Pancreat Surg 2004;11:426-429.
2. Lang BH, Poon RT, Fan ST, et al.: Influence of laparoscopy on postoperative recurrence and survival in patients with ruptured hepatocellular carcinoma undergoing hepatic resection. Br J Surg 2004;91:444-449.
3. Kaido T, Arii S, Shiota M, et al.: Repeated resection for extrahepatic recurrences after hepatectomy for ruptured hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 2004;11:149-152.
4. Yamagata M, Maeda T, Ikeda Y, et al.: Surgical results of spontaneously ruptured hepatocellular carcinoma. Hepatogastroenterology 1995;42:461-464.
5. Shirabe K, Kitamura M, Tsutsui S, et al.: A long-term survivor of ruptured hepatocellular carcinoma after hepatic resection. J Gastroenterol Hepatol 1995;10:351-354.
6. Xu HS, Yan JB: Conservative management of spontaneous ruptured hepatocellular carcinoma. Am Surg 1994;60:629-633.
7. Cavallari A, Vivarelli M, Bellusci R, et al.: The intraperitoneal bleeding of hepatocellular carcinoma. Chir Ital 1994;46:45-49.
8. Regimbeau JM, Colombat M, Mognol P, et al.: Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl 2004;10:S69-S73.
9. Yu MW, Chang HC, Chang SC, et al.: Role of reproductive factors in hepatocellular carcinoma: Impact on hepatitis B- and C-related risk. Hepatology 2003;38:1393-1400.
10. Oral contraceptives and liver cancer. Results of the Multicentre International Liver Tumor Study (MILTS). Contraception 1997;56:275-284.
11. Yamamoto T, Nagano H, Imai Y, et al.: Successful treatment of multiple hepatocellular carcinoma with tumor thrombi in the major portal branches by intraarterial 5-fluorouracil perfusion chemotherapy combined with subcutaneous interferon-alpha and hepatectomy. Int J Clin Oncol 2007;12:150-154.
12. Nakamura M, Nagano H, Sakon M, et al.: Role of the Fas/FasL pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro. J Hepatol 2007;46:77-88.
13. Kojiro S, Yano H, Ogasawara S, et al.: Antiproliferative effects of 5-fluorouracil and interferon-alpha in combination on a hepatocellular carcinoma cell line in vitro and in vivo. J Gastroenterol Hepatol 2006;21:129-137.
14. Kurokohchi K, Takaguchi K, Kita K, et al.: Successful treatment of advanced hepatocellular carcinoma by combined administration of 5-fluorouracil and pegylated interferon-alpha. World J Gastroenterol 2005;11:5401-5403.
15. Patt YZ, Hassan MM, Lozano RD, et al.: Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol 2003;21:421-427.
16. Vergara V, Muratore A, Bouzari H, et al.: Spontaneous rupture of hepatocellular carcinoma: Surgical resection and long-term survival. Eur J Surg Oncol 2000;26:770-772.
17. Chearanai O, Plengvanit U, Asavanich C, et al.: Spontaneous rupture of primary hepatoma: Report of 63 cases with particular reference to the pathogenesis and rationale treatment by hepatic artery ligation. Cancer 1983;51:1532-1536.
18. Tan FL, Tan YM, Chung AY, et al.: Factors affecting early mortality in spontaneous rupture of hepatocellular carcinoma. ANZ J Surg 2006;76:448-452.
19. Leung CS, Tang CN, Fung KH, et al.: A retrospective review of transcatheter hepatic arterial embolisation for ruptured hepatocellular carcinoma. J R Coll Surg Edinb 2002;47:685-688.
20. Recordare A, Bonariol L, Caratozzolo E, et al.: Management of spontaneous bleeding due to hepatocellular carcinoma. Minerva Chir 2002;57:347-356.
21. Marini P, Vilgrain V, Belghiti J: Management of spontaneous rupture of liver tumours. Dig Surg 2002;19:109-113.
22. Liu CL, Fan ST, Lo CM, et al.: Management of spontaneous rupture of hepatocellular carcinoma: Single-center experience. J Clin Oncol 2001;19:3725-3732.
23. Eltabbakh GH: Extreme drug resistance assay and response to chemotherapy in patients with primary peritoneal carcinoma. J Surg Oncol 2000;73:148-152.
24. Patt YZ, Hoque A, Roh M, et al.: Durable clinical and pathologic response of hepatocellular carcinoma to systemic and hepatic arterial administration of platinol, recombinant interferon alpha 2B, doxorubicin, and 5-fluorouracil: A communication. Am J Clin Oncol 1999;22:209-213.
25. Leung TW, Patt YZ, Lau WY, et al.: Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 1999;5:1676-1681.
26. Yeo W, Mok TS, Zee B, et al.: A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Nat Cancer Inst 2005;97:1532-1538.
27. Yeo W, Mok TS, Zee B, et al.: A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005;97:1532-1538.
28. Leung TW, Johnson PJ: Systemic therapy for hepatocellular carcinoma. Semin Oncol 2001;28:514-520.
29. Fausto N: Protooncogenes and growth factors associated with normal and abnormal liver growth. Dig Dis Sci 1991;36:653-658.
30. Fausto N, Mead JE: Regulation of liver growth: Protooncogenes and transforming growth factors. Lab Invest 1989;60:4-13.
31. Fausto N, Mead JE, Braun L, et al.: Proto-oncogene expression and growth factors during liver regeneration. Symp Fundam Cancer Res 1986;39:69-86.
32. Fausto N, Mead JE, Gruppuso PA, et al.: TGF-beta in liver development, regeneration, and carcinogenesis. Ann N Y Acad Sci 1990;593:231-242.
33. Fausto N, Mead JE, Gruppuso PA, et al.: Effects of TGF-beta s in the liver: Cell proliferation and fibrogenesis. Ciba Found Symp 1991;157:165-174 discussion 174-167.
34. Thomas MB, Chadha R, Iwasaki M, et al.: The Combination of Bevacizumab and Erlotinib Shows Significant Biological Activity in Patients with Advanced hepatocellular Carcinoma In "2007 American Society of Clinical Oncology Annual Meeting Proceedings." Chicago, IL 2007.